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The overwhelming majority of human cancer deaths are 
attributable to distant metastases, rather than the primary 
tumors from which these malignant lesions originate. 
Metastases arise through the completion of a series of 
complex, interrelated cell biological events - collect ively 
termed the ‘invasion-metastasis cascade’ - involving the 
dissemination of tumor cells to anatomically distant loci 
and the subsequent adaptation of these tumor cells to the 
foreign microenvironments encountered there [1]. Molecular 
mediators of these events have recently begun to be 
identified; however, our under standing of the pathogenesis 
of metastatic disease remains woefully incomplete.
One class of molecules that have been documented to 
have a crucial role in regulating the invasion-metastasis 
cascade are microRNAs (miRNAs). miRNAs are an 
evolutionarily conserved family of small regulatory RNAs 
that pleiotropically suppress gene expression through 
sequence-specific interactions with the 3’ untranslated 
regions (UTRs) of cognate mRNA targets [2]. Research 
conducted over the past 3 years has succeeded in 
elucidating various individual miRNAs that serve either 
to enhance or to impair discrete steps of the metastatic 
process [3].
Two recent studies [4,5] have now evaluated the 
consequences for metastasis of a global reduction in the 
levels of all the miRNAs produced by a cancer cell. More 
specifically, these investigators have discovered signal 
transduction pathways that lead to downregulation of the 
miRNA biogenesis enzyme Dicer and have then assessed 
the repercussions of impaired Dicer function for breast 
carcinoma metastasis (Figure 1). Dicer is an RNase III 
family endonuclease that is required for the post-trans-
criptional processing of miRNAs to their mature, 
functionally active form [2]. Previous studies have shown 
that global miRNA levels are often reduced in human 
tumor speci mens [6]; moreover, experimental inhibition 
of Dicer or other components of the miRNA biogenesis 
machinery has been reported to accelerate primary 
tumor develop ment [7]. However, the recent studies from 
the labora tories of Piccolo [4] and Flores [5] are the first 
to address the functional contributions of Dicer speci-
fically to metastatic progression.
Biting the hand that feeds: miRNA-mediated 
suppression of Dicer expression promotes metastasis
Piccolo and coworkers [4] report that the miR-103/107 
family of miRNAs directly targets the mRNA encoding 
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Figure 1. A diagram of the known components of metastasis-
controlling signal transduction cascades that involve Dicer. 
While the suppressive effects of miR-31, miR-126, miR-206, and 
miR-335 on metastasis have been directly documented in vivo [8,9], 
the roles of miR-130 and miR-200 in metastasis are implied by in vitro 
studies [3,7], but have yet to be analyzed directly in vivo.
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Dicer. Thus, these miRNAs reduce expression of the very 
enzyme that is responsible for their own biosynthesis. 
miR-103/107 and Dicer levels were found to be inversely 
correlated in several cancer cell lines and in tissue 
specimens derived directly from human breast cancer 
patients. Surprisingly, although miR-103/107 expression 
was positively associated with the propensity to suffer 
from metastatic relapse in human breast tumors, no 
significant correlation between Dicer levels and the risk 
of developing metastatic disease was found. This finding 
implies that miR-103/107 can pleiotropically regulate 
other, still-unidentified mRNA molecules that encode 
functions relevant to metastasis. Moreover, the authors 
[4] did not investigate the possibility of dynamic changes 
in Dicer and miR-103/107 levels arising from the feed-
back loop between them.
The authors [4] also discovered that overexpression of 
miR-103/107 enhanced the motility of breast carcinoma 
cells in vitro. These effects on cell motility could be 
potently reversed via forced expression of Dicer, implying 
that the ability of miR-103/107 to enhance cell motility 
was closely tied to its capacity to reduce Dicer levels. 
Further corroborating this finding was their observation 
that short hairpin RNA (shRNA)-mediated suppression 
of endogenous Dicer levels increased in vitro motility in 
these same breast carcinoma cells. Additionally, inhibi-
tion of miR-103/107 or overexpression of Dicer sufficed 
to impair the in vitro motility of otherwise-aggressive 
breast cancer cell lines. It is intriguing that Dicer over-
expression sufficed to enhance cell motility, as this 
suggests that Dicer catalytic activity can be rate-limiting 
for miRNA biogenesis - at least in the context of certain 
tumor cell lines.
miR-103/107 and Dicer also influenced the in vivo 
behaviors of breast carcinoma cells grown as tumor 
xenografts. More specifically, miR-107 overexpression 
endowed otherwise weakly metastatic breast cancer cells 
with heightened metastatic powers; these influences of 
miR-107 on metastasis were essentially abrogated by the 
concurrent forced expression of Dicer. shRNA-conferred 
suppression of the Dicer-encoding mRNA also increased 
metastasis formation in these xenograft studies [4]. In 
addition, the authors observed that either inhibition of 
miR-103/107 or overexpression of Dicer reduced the 
metastatic potential of otherwise-metastatic mammary 
carcinoma cell lines in vivo. These results show that Dicer 
expression is both necessary and sufficient to impair a 
variety of malignant attributes in vitro and in vivo, and that 
modulation of Dicer levels can explain a significant pro-
por tion of the effects of miR-103/107 on these same traits.
Finally, Piccolo and colleagues [4] showed that miR-107 
overexpression or shRNA-mediated suppression of Dicer 
triggered an epithelial-mesenchymal transition (EMT) in 
normal mammary epithelial cells. Because the EMT has 
previously been linked to the promotion of motile 
behavior in carcinoma cells [1], they reasoned that loss of 
Dicer expression might enhance cell motility through the 
induction of an EMT, presumably by disrupting miRNA-
controlled fate decisions. Indeed, they found that modu-
lating miR-103/107 levels altered the activity of miR-200 - 
a crucial EMT-inhibitory miRNA [3] - in their cell culture 
models. However, the authors [4] did not address the 
relevance of these miR-200-dependent signaling events 
for in vivo metastatic abilities, nor did they determine the 
contributions of other known anti-metastatic miRNAs - 
such as miR-31, miR-126, miR-206 and miR-335 [8,9] - 
for mediating the observed anti-malignant responses. 
Together, the work of Piccolo and colleagues [4] shows 
that Dicer can be post-transcriptionally suppressed by 
miR-103/107, leading to enhanced metastatic capacity 
following the dampening activity of the metastasis-
suppressing Dicer enzyme.
Upregulation of Dicer expression by TaP63 
suppresses metastasis
Dicer expression levels are controlled by several different 
signaling pathways. The recent findings of Flores and 
coworkers [5] - which highlight one mechanism by which 
transcription of the Dicer gene is controlled - are there-
fore highly significant. In this study, the authors [5] noted 
that mice engineered to be genetically deficient for the 
p53-related transcription factor TaP63 developed 
metastatic tumors with an increased frequency. In fact, 
whereas TaP63+/- and TaP63-/- mice contracted metastatic 
carcinomas with an equivalent prevalence, the TaP63+/- 
animals were at an even higher risk for developing 
metastatic sarcomas than were the TaP63-/- mice; the 
mecha nistic rationale underlying this observation remains 
imprecisely defined and merits further investigation [5].
The Flores laboratory [5] hypothesized - because of 
similarities of the haploinsufficiency of TaP63 for tumor 
suppression, and also of the embryonic lethality of 
TaP63-/- mice on an enriched C57Bl/6 background before 
embryonic day 8.5, with the previously reported 
corresponding phenotypes of Dicer conditional knockout 
animals [10] - that TaP63 and Dicer might operate within 
the same biochemical pathway. Indeed, they discovered 
that levels of the Dicer-encoding mRNA were dramati-
cally reduced in cell lines derived from TaP63-deficient 
animals; furthermore, low expression of TaP63 was 
correlated with low Dicer levels in patient-derived meta-
static human tumor specimens. In addition, the authors 
[5] showed using chromatin immuno precipi tation (ChIP) 
analyses that TaP63 can bind directly to the promoter 
region of Dicer. Therefore, TaP63 can directly regulate 
expression levels of Dicer.
In functional assays, the authors [5] discovered that 
forced expression of Dicer reversed the increased 
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invasiveness elicited by TaP63 deficiency in vitro. 
Increased invasion was also triggered by the shRNA-
conferred suppression of endogenous Dicer levels in the 
same in vitro assays. However, the effects of modulating 
Dicer levels on the in vivo metastatic behaviors of carci-
noma cells were not investigated in this study [5]; this is a 
crucial topic for future investigation, as rigorous analysis 
of metastatic attributes requires detailed in vivo analyses.
The authors [5] also undertook to identify additional 
transcriptional targets of TaP63 that might also be 
important for mediating its influences on the aggressive 
behaviors of carcinoma cells. One such downstream 
effector of TaP63 was found to be the miRNA miR-130b. 
Direct binding of TaP63 to the putative miR-130b 
promoter sequence was documented by ChIP experi-
ments. Also, in functional assays, inhibition of miR-130b 
resulted in increased motility in vitro - a phenotype 
reminiscent of the cell-biological changes elicited by 
modulation of the expression levels of either TaP63 or 
Dicer itself. The augmented in vitro invasiveness 
observed in cell lines derived from TaP63-deficient mice 
could be completely reversed by the concomitant over-
expression of miR-130b and Dicer. The data of Flores and 
colleagues [5] therefore imply that TaP63 can alter certain 
cellular behaviors - such as invasiveness - that are 
believed to be important for the acquisition of a 
metastatic phenotype via the coordinate transcriptional 
regulation of Dicer and miR-130b.
Conceptual and therapeutic implications
The work of the Piccolo [4] and Flores [5] laboratories 
reveal that Dicer functions as a potent suppressor of 
metastatic attributes in breast carcinoma cells. Given the 
diverse roles of various individual miRNAs during the 
invasion-metastasis cascade - including both metastasis-
promoting effects and metastasis-suppressive influences 
[3] - it is striking that a global reduction of miRNA 
activity results in such a clear and unambiguous pheno-
type in multiple different breast carcinoma cell lines. An 
important direction for future research will involve 
determining whether Dicer has a similar metastasis-
suppressive role in carcinomas derived from tissue types 
other than the breast. From a practical standpoint, 
however, it seems highly likely that the critical functions 
orchestrated by miRNAs in a wide spectrum of different 
tissue and cell types will preclude the development of 
anti-Dicer-based therapeutic agents designed to block 
metastatic disease.
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